{"title":"[关于新开发抗结核药物用于耐多药结核病的考虑]。","authors":"Toru Mori, Kenji Ogawa, Eriko Shigeto, Tadao Shimao, Katsuhiro Suzuki, Kazunari Tsuyuguchi, Hideaki Nagai, Tomoshige Matsumoto, Satoshi Mitarai, Takashi Yoshiyama","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.</p>","PeriodicalId":17997,"journal":{"name":"Kekkaku : [Tuberculosis]","volume":"89 11","pages":"813-5"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Considerations on uses of newly developed anti-tuberculosis drugs for multi-drug resistant tuberculosis].\",\"authors\":\"Toru Mori, Kenji Ogawa, Eriko Shigeto, Tadao Shimao, Katsuhiro Suzuki, Kazunari Tsuyuguchi, Hideaki Nagai, Tomoshige Matsumoto, Satoshi Mitarai, Takashi Yoshiyama\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.</p>\",\"PeriodicalId\":17997,\"journal\":{\"name\":\"Kekkaku : [Tuberculosis]\",\"volume\":\"89 11\",\"pages\":\"813-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kekkaku : [Tuberculosis]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kekkaku : [Tuberculosis]","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Considerations on uses of newly developed anti-tuberculosis drugs for multi-drug resistant tuberculosis].
We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.